Faster-acting insulin aspart reduces glycaemic variability in sensor-augmented pump treated type 1 diabetes patients

被引:1
|
作者
Moreno-Fernandez, Jesus [1 ]
Garcia-Seco, Jose Alberto [1 ]
Virlaboa-Cebrian, Rita [1 ]
Seco, Angela Maria [1 ]
Munoz-Rodriquez, Jose Ramon [2 ]
Gomez-Romero, Francisco Javier [3 ]
机构
[1] Ciudad Real Gen Univ Hosp, Endocrinol & Nutr Dept, Ciudad Real, Spain
[2] Ciudad Real Gen Univ Hosp, Translat Res Unit, Ciudad Real, Spain
[3] Ciudad Real Gen Univ Hosp, Invest Support Unit, Ciudad Real, Spain
来源
ENDOCRINOLOGIA DIABETES Y NUTRICION | 2023年 / 70卷 / 06期
关键词
Faster-acting insulin aspart; Glycaemic variability; Treatment; Insulin pump; Type; 1; diabetes; THERAPY; RISK;
D O I
10.1016/j.endinu.2021.12.011
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aim: To evaluate the effect of faster aspart over glycaemic variability in type 1 diabetes (T1D) patients treated with sensor-augmented pump (SAP) in a real-world scenario. Methods: Observational study with SAP-treated adult T1D patients treated with faster aspart for three months. The primary endpoint was the mean amplitude of glucose excursions (MAGE).Results: Fifty patients were treated with faster aspart. Eleven patients (23%) withdrew during the follow-up mainly due to worsening of diabetes control (9 patients). Mean age was 41.2 yrs. (range 21-59) and T1D duration 22.4 & PLUSMN; 10.0 yrs. Mean SAP treatment duration was 3.6 & PLUSMN; 3.1 yrs. We detected a reduction of-7.0 (95% CI -1.1, -12.9; p = 0.021) in MAGE at the end of the study. Other glycemic variability indices were also improved: standard deviation of mean interstitial glucose (-3 mg/dl; 95% CI, -1, -5; p = 0.01), CONGA4 (-2.2; 95% CI -0.3, -4.2; p = 0.029), CONGA6 (-2.6; 95% CI -0.6, -4.6; p = 0.011), GRADE (-0.5; 95% CI -0.1, -0.9; p = 0.022), HBGI (-0.7; 95% CI -0.2, -1.3; p = 0.013), J-index (-2.9; 95% CI -0.7, -5.0; p = 0.011) and MODD (-5.7; 95% CI -1.7, -9.7; p = 0.006). A slight reduction in mean glucose management indicator was also detected (-0.14%; 95% CI, -0.02, -0.27; -1.4 mmol/mol; 95% CI -0.1, -3.3; p = 0.03).Conclusions: In SAP-treated T1D patients, faster aspart insulin was associated with reduced glycaemic variability, but also a high percentage of dropouts due to worsened glycaemic control. NCT04233203. & COPY; 2022 SEEN y SED. Published by Elsevier Espana, S.L.U. All rights reserved.
引用
收藏
页码:389 / 395
页数:7
相关论文
共 50 条
  • [1] Faster-acting insulin Fiasp versus insulin Novorapid in type 1 diabetes children and adolescents with sensor-augmented pump therapy
    Xatzipsalti, Maria
    Triantafillidou, Antigoni
    Kourousi, Giannoula
    Patouni, Konstantina
    Bourousis, Evangelos
    Kassari, Elisavet
    Delis, Dimitrios
    Vazeou, Andriani
    [J]. HORMONE RESEARCH IN PAEDIATRICS, 2022, 95 (SUPPL 2): : 182 - 182
  • [2] Faster-Acting Insulin Aspart vs. Insulin Aspart for Adults with Type 1 Diabetes Treated with Insulin Pump and Continuous Glucose Monitoring
    Ranjan, Ajenthen G.
    Schmidt, Signe
    Andersen, Hanne-Charlotte
    Norgaard, Kirsten
    [J]. DIABETES, 2024, 73
  • [3] The impact of of "faster aspart" on blood glucose control in children and adolescents with type 1 diabetes treated using a sensor-augmented insulin pump
    de Buitrago Amigo, Jesus Gonzalez
    Gonzalez Garcia, Ana
    Diaz Fernandez, Paula
    Fernandez Llamas, Mercedes
    Tejado Bravo, Maria Luz
    de Nicolas Jimenez, Jorge M.
    Ferrer Lozano, Marta
    [J]. ANALES DE PEDIATRIA, 2021, 95 (05): : 321 - 329
  • [4] Faster-acting insulin aspart improves postprandial glycaemia versus insulin aspart in patients with type 1 diabetes mellitus
    Heise, T.
    Haahr, H.
    Jensen, L.
    Erichsen, L.
    Hompesch, M.
    [J]. DIABETOLOGIA, 2014, 57 : S57 - S57
  • [5] IMPROVED POSTPRANDIAL GLYCAEMIC CONTROL WITH FASTER-ACTING INSULIN ASPART VS INSULIN ASPART IN SUBJECTS WITH TYPE 1 DIABETES USING CSII IN PUMPS
    Bode, B. W.
    Hyveled, L.
    Tamer, S. C.
    Demissie, M.
    [J]. DIABETES TECHNOLOGY & THERAPEUTICS, 2016, 18 : A40 - A40
  • [6] Improved postprandial glycaemic control with faster-acting insulin aspart in individuals with type 1 diabetes using CSII
    Bode, B. W.
    Hyveled, L.
    Tamer, S. C.
    Ybanez, P.
    Demissie, M.
    [J]. DIABETOLOGIA, 2015, 58 : S19 - S19
  • [7] FASTER-ACTING INSULIN ASPART IMPROVES POSTPRANDIAL GLYCAEMIA VERSUS INSULIN ASPART IN PATIENTS WITH TYPE 1 DIABETES MELLITUS
    Heise, T.
    Haahr, H.
    Jensen, L.
    Erichsen, L.
    Hompesch, M.
    [J]. DIABETES TECHNOLOGY & THERAPEUTICS, 2015, 17 : A5 - A6
  • [8] POSTPRANDIAL GLYCEMIC CONTROL WITH FAST-ACTING INSULIN ASPART IN PATIENTS WITH TYPE 1 DIABETES USING SENSOR-AUGMENTED PUMP THERAPY
    Pazos-Couselo, M.
    Garcia-Lopez, J. M.
    Fernandez-Pombo, A.
    Gonzalez-Rodriguez, M.
    [J]. DIABETES TECHNOLOGY & THERAPEUTICS, 2020, 22 : A93 - A93
  • [9] Copenfast trial: foetal growth and glycaemic control in pregnant women with type 1 or type 2 diabetes randomised to faster-acting insulin aspart or insulin aspart
    Norgaard, S.
    Soholm, J.
    Mathiesen, E.
    Norgaard, K.
    Clausen, T.
    Holmager, P.
    Do, N.
    Damm, P.
    Ringholm, L.
    [J]. DIABETOLOGIA, 2023, 66 (SUPPL 1) : S122 - S122
  • [10] PROJECTED LONG-TERM OUTCOMES IN PATIENTS WITH TYPE 1 DIABETES MELLITUS TREATED WITH FASTER-ACTING INSULIN ASPART VERSUS CONVENTIONAL INSULIN ASPART IN THE UK SETTING
    Russell-Jones, D.
    Buchs, S.
    Jensen, M. M.
    Hunt, B.
    Valentine, W. J.
    Heller, S.
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A671 - A671